BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

(2013) A. R. Chakraborty et al.   BLOOD

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts

(2013) S L Locatelli et al.   LEUKEMIA

Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells

(2013) Carmelo Carlo-Stella et al.   PLoS One

Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma

(2012) E. Tiacci et al.   BLOOD

Phase II study of sorafenib in patients with relapsed or refractory lymphoma

(2012) Anna Guidetti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo

(2012) R. Coriat et al.   MOLECULAR CANCER THERAPEUTICS

Novel Agents in Hodgkin Lymphoma

(2012) Alison J. Moskowitz   Current Oncology Reports

Necroptosis: An emerging form of programmed cell death

(2011) Wei Wu et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

(2011) Anas Younes et al.   LANCET ONCOLOGY

Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells

(2011) Luca A. Petruccelli et al.   PLoS One

Emerging drugs for Hodgkin's lymphoma

(2010) Boris Böll et al.   EXPERT OPINION ON EMERGING DRUGS

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

(2010) Michael Dickinson et al.   INVESTIGATIONAL NEW DRUGS

Role of Bim in diallyl trisulfide-induced cytotoxicity in human cancer cells

(2010) Byeong-Chel Lee et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Developments in the management of Hodgkin's lymphoma

(2010) Lisa Lowry et al.   LANCET

Beyond chemotherapy: new agents for targeted treatment of lymphoma

(2010) Anas Younes   Nature Reviews Clinical Oncology

Molecular mechanisms of necroptosis: an ordered cellular explosion

(2010) Peter Vandenabeele et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR Signaling and Drug Discovery

(2010) Georg Lurje et al.   ONCOLOGY

Bcl2 family proteins in carcinogenesis and the treatment of cancer

(2009) Anna Frenzel et al.   APOPTOSIS

New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue

(2009) Jeannine C. Franke et al.   BIOCHEMICAL PHARMACOLOGY

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

(2009) Alison J. Moskowitz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF- B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

(2009) S. Bhalla et al.   CLINICAL CANCER RESEARCH

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1-induced apoptosis in breast cancer cells

(2009) U. M. Schneiders et al.   MOLECULAR CANCER THERAPEUTICS

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION

Histone deacetylase inhibitors in lymphoma and solid malignancies

(2008) Walid Rasheed et al.   Expert Review of Anticancer Therapy

Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant

(2008) M. Crump   Hematology-American Society of Hematology Education Program

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

(2007) P. G. Longo et al.   BLOOD

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY